{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:31:10Z","timestamp":1789594270553,"version":"build-2803163510"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:p>Aramchol, an oral stearoyl\u2010coenzyme\u2010A\u2010desaturase\u20101 inhibitor, has been shown to reduce hepatic fat content in patients with primary nonalcoholic fatty liver disease (NAFLD); however, its effect in patients with human immunodeficiency virus (HIV)\u2013associated NAFLD is unknown. The aramchol for HIV\u2010associated NAFLD and lipodystrophy (ARRIVE) trial was a double\u2010blind, randomized, investigator\u2010initiated, placebo\u2010controlled trial to test the efficacy of 12 weeks of treatment with aramchol versus placebo in HIV\u2010associated NAFLD. Fifty patients with HIV\u2010associated NAFLD, defined by magnetic resonance imaging (MRI)\u2013proton density fat fraction (PDFF) \u22655%, were randomized to receive either aramchol 600 mg daily (n\u00a0=\u00a025) or placebo (n\u00a0=\u00a025) for 12 weeks. The primary endpoint was a change in hepatic fat as measured by MRI\u2010PDFF in colocalized regions of interest. Secondary endpoints included changes in liver stiffness using magnetic resonance elastography (MRE) and vibration\u2010controlled transient elastography (VCTE), and exploratory endpoints included changes in total\u2010body fat and muscle depots on dual\u2010energy X\u2010ray absorptiometry (DXA), whole\u2010body MRI, and cardiac MRI. The mean (\u00b1 standard deviation) of age and body mass index were 48.2\u00a0\u00b1\u00a010.3 years and 30.7\u00a0\u00b1\u00a04.6 kg\/m<jats:sup>2<\/jats:sup>, respectively. There was no difference in the reduction in mean MRI\u2010PDFF between the aramchol group at \u20131.3% (baseline MRI\u2010PDFF 15.6% versus end\u2010of\u2010treatment MRI\u2010PDFF 14.4%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0=\u00a00.24) and the placebo group at \u20131.4% (baseline MRI\u2010PDFF 13.3% versus end\u2010of\u2010treatment MRI\u2010PDFF 11.9%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0=\u00a00.26). There was no difference in the relative decline in mean MRI\u2010PDFF between the aramchol and placebo groups (6.8% versus 1.1%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u00a0=\u00a00.68). There were no differences in MRE\u2010derived and VCTE\u2010derived liver stiffness and whole\u2010body (fat and muscle) composition analysis by MRI or DXA. Compared to baseline, end\u2010of\u2010treatment aminotransferases were lower in the aramchol group but not in the placebo arm. There were no significant adverse events. <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>: Aramchol, over a 12\u2010week period, did not reduce hepatic fat or change body fat and muscle composition by using MRI\u2010based assessment in patients with HIV\u2010associated NAFLD (clinicaltrials.gov ID:NCT02684591).<\/jats:p>","DOI":"10.1002\/hep.30674","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T16:18:02Z","timestamp":1556036282000},"page":"1531-1545","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":41,"title":["MRI Assessment of Treatment Response in HIV\u2010associated NAFLD: A Randomized Trial of a Stearoyl\u2010Coenzyme\u2010A\u2010Desaturase\u20101 Inhibitor (ARRIVE Trial)"],"prefix":"10.1097","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5626-0942","authenticated-orcid":false,"given":"Veeral H.","family":"Ajmera","sequence":"first","affiliation":[{"name":"NAFLD Research Center,University of California San Diego Health,La Jolla,CA"},{"name":"Division of Gastroenterology, Department of Medicine,University of California San Diego Health,La Jolla,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Cachay","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases,Owen Clinic, University of California San Diego,San Diego,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ramers","sequence":"additional","affiliation":[{"name":"Family Health Center,San Diego,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irine","family":"Vodkin","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine,University of California San Diego Health,La Jolla,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Bassirian","sequence":"additional","affiliation":[{"name":"NAFLD Research Center,University of California San Diego Health,La Jolla,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Singh","sequence":"additional","affiliation":[{"name":"NAFLD Research Center,University of California San Diego Health,La Jolla,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Mangla","sequence":"additional","affiliation":[{"name":"NAFLD Research Center,University of California San Diego Health,La Jolla,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richele","family":"Bettencourt","sequence":"additional","affiliation":[{"name":"NAFLD Research Center,University of California San Diego Health,La Jolla,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette L.","family":"Aldous","sequence":"additional","affiliation":[{"name":"San Ysidro Health,San Diego,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Park","sequence":"additional","affiliation":[{"name":"San Ysidro Health,San Diego,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2959-890X","authenticated-orcid":false,"given":"Daniel","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases,Owen Clinic, University of California San Diego,San Diego,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Blanchard","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases,Owen Clinic, University of California San Diego,San Diego,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrija","family":"Mamidipalli","sequence":"additional","affiliation":[{"name":"Liver Imaging Group,University of California San Diego,La Jolla,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Boehringer","sequence":"additional","affiliation":[{"name":"Liver Imaging Group,University of California San Diego,La Jolla,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Aslam","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health,University of California San Diego,San Diego,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof Dahlqvist","family":"Leinhard","sequence":"additional","affiliation":[{"name":"AMRA Medical AB,Link\u00f6ping,Sweden"},{"name":"Department of Medical and Health Sciences,Link\u00f6ping University,Link\u00f6ping,Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Richards","sequence":"additional","affiliation":[{"name":"NAFLD Research Center,University of California San Diego Health,La Jolla,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Sirlin","sequence":"additional","affiliation":[{"name":"Liver Imaging Group,University of California San Diego,La Jolla,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[{"name":"NAFLD Research Center,University of California San Diego Health,La Jolla,CA"},{"name":"Division of Gastroenterology, Department of Medicine,University of California San Diego Health,La Jolla,CA"},{"name":"Division of Epidemiology, Department of Family and Preventive Medicine,University of California San Diego,La Jolla,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,6,18]]},"reference":[{"key":"hep30674-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta\u2010analytic assessment of prevalence, incidence, and outcomes","volume":"64","year":"2016","journal-title":"Hepatology"},{"key":"hep30674-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"hep30674-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","article-title":"Liver\u2010related deaths in persons infected with the human immunodeficiency virus: the D:A: D study","volume":"166","year":"2006","journal-title":"Arch Intern Med"},{"key":"hep30674-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1097\/QAD.0000000000001504","article-title":"Prevalence and risk factors of nonalcoholic fatty liver disease in HIV\u2010monoinfection","volume":"31","year":"2017","journal-title":"Aids"},{"key":"hep30674-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/apt.13052","article-title":"Clinical, biochemical and histological differences between HIV\u2010associated NAFLD and primary NAFLD: a case\u2013control study","volume":"41","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"hep30674-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/QAI.0b013e318074efe3","article-title":"HIV\u2010positive patients with nonalcoholic fatty liver disease have a lower body mass index and are more physically active than HIV\u2010negative patients","volume":"45","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"hep30674-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/ajg.2014.32","article-title":"Risk factors for fatty liver in the Multicenter AIDS Cohort Study","volume":"109","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"hep30674-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/infdis\/jiu409","article-title":"Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection","volume":"211","year":"2015","journal-title":"J Infect Dis"},{"key":"hep30674-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo\u2010controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep30674-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep30674-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator\u2013activated receptor\u2010alpha and \u2010delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","year":"2016","journal-title":"Gastroenterology"},{"key":"hep30674-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00042737-200306000-00012","article-title":"Biliary and systemic effects of fatty acid bile acid conjugates","volume":"15","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"hep30674-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.cgh.2014.04.038","article-title":"The fatty acid\u2013bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease","volume":"12","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep30674-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/hep.25731","article-title":"Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial","volume":"56","year":"2012","journal-title":"Hepatology"},{"key":"hep30674-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/apt.12237","article-title":"Association between novel MRI\u2010estimated pancreatic fat and liver histology\u2010determined steatosis and fibrosis in non\u2010alcoholic fatty liver disease","volume":"37","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"hep30674-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1136\/gutjnl-2015-309456","article-title":"Serum microRNAs explain discordance of non\u2010alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study","volume":"65","year":"2016","journal-title":"Gut"},{"key":"hep30674-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1053\/j.gastro.2015.08.011","article-title":"Heritability of hepatic fibrosis and steatosis based on a prospective twin study","volume":"149","year":"2015","journal-title":"Gastroenterology"},{"key":"hep30674-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","article-title":"Magnetic resonance elastography versus transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy\u2010proven nonalcoholic fatty liver disease","volume":"152","year":"2017","journal-title":"Gastroenterology"},{"key":"hep30674-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1148\/radiol.2017160606","article-title":"Quantifying abdominal adipose tissue and thigh muscle volume and hepatic proton density fat fraction: repeatability and accuracy of an MR imaging\u2010based, semiautomated analysis method","volume":"283","year":"2017","journal-title":"Radiology"},{"key":"hep30674-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.27647","article-title":"Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)","volume":"61","year":"2015","journal-title":"Hepatology"},{"key":"hep30674-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin versus. placebo for non\u2010alcoholic fatty liver disease: a randomized controlled trial","volume":"65","year":"2016","journal-title":"J Hepatol"},{"key":"hep30674-bib-0022-20241017","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/hep.25731","article-title":"Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial","volume":"56","year":"2012","journal-title":"Hepatology"},{"key":"hep30674-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2036.2012.05121.x","article-title":"Correlation between liver histology and novel magnetic resonance imaging in adult patients with non\u2010alcoholic fatty liver disease\u2014MRI accurately quantifies hepatic steatosis in NAFLD","volume":"36","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"hep30674-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1148\/radiol.12120896","article-title":"Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis","volume":"267","year":"2013","journal-title":"Radiology"},{"key":"hep30674-bib-0025-20241017","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/jmri.22580","article-title":"Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy","volume":"34","year":"2011","journal-title":"J Magn Reson Imaging"},{"key":"hep30674-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","article-title":"Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography","volume":"150","year":"2016","journal-title":"Gastroenterology"},{"key":"hep30674-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.2353\/ajpath.2008.071021","article-title":"Insulin\u2010like growth factor\u2010II is increased in systemic sclerosis\u2010associated pulmonary fibrosis and contributes to the fibrotic process via Jun N\u2010terminal kinase\u2010 and phosphatidylinositol\u20103 kinase\u2010dependent pathways","volume":"172","year":"2008","journal-title":"Am J Pathol"},{"key":"hep30674-bib-0028-20241017","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","article-title":"Transient elastography: a new noninvasive method for assessment of hepatic fibrosis","volume":"29","year":"2003","journal-title":"Ultrasound Med Biol"},{"key":"hep30674-bib-0029-20241017","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","article-title":"Non\u2010invasive evaluation of liver fibrosis using transient elastography","volume":"48","year":"2008","journal-title":"J Hepatol"},{"key":"hep30674-bib-0030-20241017","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/hep.29639","article-title":"Optimal threshold of controlled attenuation parameter with MRI\u2010PDFF as the gold standard for the detection of hepatic steatosis","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep30674-bib-0031-20241017","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1002\/nbm.3432","article-title":"Validation of a fast method for quantification of intra\u2010abdominal and subcutaneous adipose tissue for large\u2010scale human studies","volume":"28","year":"2015","journal-title":"NMR Biomed"},{"key":"hep30674-bib-0032-20241017","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/oby.22210","article-title":"Body composition profiling in the UK Biobank imaging study","volume":"26","year":"2018","journal-title":"Obesity (Silver Spring)"},{"key":"hep30674-bib-0033-20241017","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS\u20100976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease","volume":"155","year":"2018","journal-title":"Gastroenterology"},{"key":"hep30674-bib-0034-20241017","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/hep.26455","article-title":"Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials","volume":"58","year":"2013","journal-title":"Hepatology"},{"key":"hep30674-bib-0035-20241017","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","article-title":"Magnetic resonance versus transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants","volume":"17","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep30674-bib-0036-20241017","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijcard.2018.01.106","article-title":"Pericardial and visceral, but not total body fat, are related to global coronary and extra\u2010coronary atherosclerotic plaque burden","volume":"260","year":"2018","journal-title":"Int J Cardiol"},{"key":"hep30674-bib-0037-20241017","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.dld.2017.12.014","article-title":"Effect of longitudinal changes of body fat on the incidence and regression of nonalcoholic fatty liver disease","volume":"50","year":"2018","journal-title":"Dig Liver Dis"},{"key":"hep30674-bib-0038-20241017","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1097\/QAD.0000000000001248","article-title":"Long\u2010term body composition changes in antiretroviral\u2010treated HIV\u2010infected individuals","volume":"30","year":"2016","journal-title":"Aids"},{"key":"hep30674-bib-0039-20241017","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.29797","article-title":"Non\u2010invasive, quantitative assessment of liver fat by MRI\u2010PDFF as an endpoint in NASH trials","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"hep30674-bib-0040-20241017","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jhep.2017.11.028","article-title":"Role of imaging\u2010based biomarkers in NAFLD: recent advances in clinical application and future research directions","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"hep30674-bib-0041-20241017","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1161\/01.CIR.0000099542.57313.C5","article-title":"Human epicardial adipose tissue is a source of inflammatory mediators","volume":"108","year":"2003","journal-title":"Circulation"},{"key":"hep30674-bib-0042-20241017","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jacc.2012.11.062","article-title":"Association of epicardial fat with cardiovascular risk factors and incident myocardial infarction in the general population: the Heinz Nixdorf Recall study","volume":"61","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"hep30674-bib-0043-20241017","first-page":"1569","article-title":"Nonalcoholic steatohepatitis and hepatic fibrosis in HIV\u20101\u2010monoinfected adults with elevated aminotransferase levels on antiretroviral therapy","volume":"60","year":"2015","journal-title":"Clin Infect Dis"},{"key":"hep30674-bib-0044-20241017","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/QAI.0b013e31829f919d","article-title":"Microbial translocation in HIV infection is associated with dyslipidemia, insulin resistance, and risk of myocardial infarction","volume":"64","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"hep30674-bib-0045-20241017","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200203290-00002","article-title":"Indinavir acutely inhibits insulin\u2010stimulated glucose disposal in humans: a randomized, placebo\u2010controlled study","volume":"16","year":"2002","journal-title":"Aids"},{"key":"hep30674-bib-0046-20241017","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1053\/j.gastro.2018.04.014","article-title":"Magnetic resonance imaging proton density fat fraction associates with progression of fibrosis in patients with nonalcoholic fatty liver disease","volume":"155","year":"2018","journal-title":"Gastroenterology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.30674","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.30674","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.30674","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.30674","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:34:42Z","timestamp":1729211682000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.30674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,18]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.30674","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,18]]},"assertion":[{"value":"2019-01-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}